Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited Fundamental Analysis
Genor Biopharma Holdings Limited (6998.HK) shows moderate financial fundamentals with a PE ratio of 5.63, profit margin of 16.01%, and ROE of 15.81%. The company generates $1.0B in annual revenue with weak year-over-year growth of 0.00%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 49.2/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 6998.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak6998.HK struggles to generate sufficient returns from assets.
Valuation Score
Excellent6998.HK trades at attractive valuation levels.
Growth Score
Moderate6998.HK shows steady but slowing expansion.
Financial Health Score
Moderate6998.HK shows balanced financial health with some risks.
Profitability Score
Excellent6998.HK achieves industry-leading margins.
Key Financial Metrics
Is 6998.HK Expensive or Cheap?
P/E Ratio
6998.HK trades at 5.63 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, 6998.HK's PEG of 0.00 indicates potential undervaluation.
Price to Book
The market values Genor Biopharma Holdings Limited at 0.57 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 0.62 times EBITDA. This is generally considered low.
How Well Does 6998.HK Make Money?
Net Profit Margin
For every $100 in sales, Genor Biopharma Holdings Limited keeps $16.01 as profit after all expenses.
Operating Margin
Core operations generate 16.20 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $15.81 in profit for every $100 of shareholder equity.
ROA
Genor Biopharma Holdings Limited generates $5.93 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Genor Biopharma Holdings Limited produces operating cash flow of $102.39M, showing steady but balanced cash generation.
Free Cash Flow
Genor Biopharma Holdings Limited produces free cash flow of $84.19M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.16 in free cash annually.
FCF Yield
6998.HK converts 24.32% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
5.63
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.005
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.57
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.36
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.39
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.16
vs 25 benchmark
ROA
Return on assets percentage
0.06
vs 25 benchmark
ROCE
Return on capital employed
0.09
vs 25 benchmark
How 6998.HK Stacks Against Its Sector Peers
| Metric | 6998.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 5.63 | 28.32 | Better (Cheaper) |
| ROE | 15.81% | 733.00% | Weak |
| Net Margin | 16.01% | -53055.00% (disorted) | Strong |
| Debt/Equity | 0.39 | 0.38 | Neutral |
| Current Ratio | 1.00 | 4.03 | Weak Liquidity |
| ROA | 5.93% | -19488.00% (disorted) | Weak |
6998.HK outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Genor Biopharma Holdings Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
1381.67%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
90.81%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-3.38%
Industry Style: Defensive, Growth, Innovation
Declining